Affymetrix Says Adoption of Lower-Priced Products Contributed to 4 Percent Fall in Q4 Revenue

Officials attributed the drop to a "major slowdown in scientific services" and "lower-than-expected sales within the discovery segment of our business," but Affy's CEO noted the company's annual free cash generation could make it more acquisitive going forward.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.